T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Embecta
EMBC
$290M
| $880K | ﹤0.01% |
74,010
+5,929
| +9% | +$78.2K |
|
2127
FuboTV Inc
FUBO
$293M
| $879K | ﹤0.01% |
29,047
+987
| +4% | +$39.4K |
|
2128
Deluxe
DLX
$1.09B
| $878K | ﹤0.01% |
39,306
-4,666
| -11% | -$93.9K |
|
|
DEA
2129
Easterly Government Properties
DEA
$1.16B
| $875K | ﹤0.01% |
41,290
+1,049
| +3% | +$22.8K |
|
|
ALEX
2130
DELISTED
Alexander & Baldwin
ALEX
| $871K | ﹤0.01% |
42,172
+2,364
| +6% | +$41.1K |
|
2131
Schneider National
SNDR
$6.27B
| $868K | ﹤0.01% |
32,688
-1,552
| -5% | -$36.6K |
|
2132
Apogee Enterprises
APOG
$897M
| $865K | ﹤0.01% |
23,754
+207
| +0.9% | +$7.83K |
|
2133
Western New England Bancorp
WNEB
$282M
| $864K | ﹤0.01% |
68,387
+2,405
| +4% | +$28.9K |
|
|
AAT
2134
American Assets Trust
AAT
$1.39B
| $863K | ﹤0.01% |
45,587
+1,818
| +4% | +$35.1K |
|
|
JAMF
2135
DELISTED
Jamf
JAMF
| $860K | ﹤0.01% |
66,078
-6,776
| -9% | -$82.2K |
|
|
CLDT
2136
Chatham Lodging
CLDT
$590M
| $859K | ﹤0.01% |
126,016
+19,278
| +18% | +$128K |
|
2137
Ingles Markets
IMKTA
$1.66B
| $857K | ﹤0.01% |
12,494
+589
| +5% | +$42.8K |
|
2138
Enact Holdings
ACT
$6.79B
| $854K | ﹤0.01% |
21,542
-3,909
| -15% | -$147K |
|
|
NTST
2139
NETSTREIT Corp
NTST
$2.08B
| $851K | ﹤0.01% |
48,215
-2,610
| -5% | -$47.5K |
|
2140
DXP Enterprises
DXPE
$3.04B
| $850K | ﹤0.01% |
7,737
+800
| +12% | +$87.1K |
|
2141
Ouster
OUST
$3.25B
| $848K | ﹤0.01% |
39,143
+12,028
| +44% | +$318K |
|
2142
Navitas Semiconductor
NVTS
$3.57B
| $839K | ﹤0.01% |
117,472
+44,294
| +61% | +$426K |
|
|
ADAM
2143
Adamas Trust
ADAM
$913M
| $839K | ﹤0.01% |
114,877
+12,410
| +12% | +$88.1K |
|
2144
ANI Pharmaceuticals
ANIP
$1.72B
| $834K | ﹤0.01% |
10,553
+850
| +9% | +$73.6K |
|
|
BOW
2145
Bowhead Specialty Holdings
BOW
$1.11B
| $831K | ﹤0.01% |
29,098
+7,257
| +33% | +$193K |
|
|
CIM
2146
Chimera Investment
CIM
$991M
| $825K | ﹤0.01% |
66,323
-23,496
| -26% | -$298K |
|
2147
F&G Annuities & Life
FG
$3.48B
| $825K | ﹤0.01% |
26,725
+15,529
| +139% | +$486K |
|
2148
Ennis
EBF
$556M
| $824K | ﹤0.01% |
45,706
-3,875
| -8% | -$67.5K |
|
2149
Lifestance Health
LFST
$4.67B
| $824K | ﹤0.01% |
117,013
+35,563
| +44% | +$215K |
|
2150
Utah Medical Products
UTMD
$230M
| $823K | ﹤0.01% |
14,680
-1,484
| -9% | -$86K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.